This chapter describes trade name, classification, approved indications for psychological disorders, available dosage forms, storage, and compatibility, usual dosage and administration, relative contraindications, and clinically significant drug interactions of Paroxetine. Safety and efficacy of Zolpidem pharmacotherapy for women who are breast-feeding and their neonates and infants have not been established. Avoid prescribing Zolpidem pharmacotherapy to women who are breast-feeding. Zolpidem pharmacotherapy has been associated with the development of problematic patterns of use, including addiction and habituation. Prescribe Zolpidem only for the short-term symptomatic management of insomnia associated with disturbed sleep that results in impaired daytime functioning. Zolpidem pharmacotherapy commonly has been associated with dizziness, drowsiness, incoordination, and lightheadedness. Signs and symptoms of Zolpidem overdosage primarily involve impairment of consciousness ranging from drowsiness to light coma. Zolpidem overdosage requires emergency symptomatic medical support of body systems with attention to increasing Zolpidem elimination.